IL-2/LAK cell treatment for advanced cancers with emphasis on a novel administration

W V Med J. 1991 Aug;87(8):344-6.

Abstract

Interleukin-2 (IL-2) is a substance produced by activated blood cells called helper T-lymphocytes and has been shown to stimulate the body's immune system. IL-2 may cause certain tumors to regress when administered intravenously to laboratory animals and humans. Lymphokine activated killer (LAK) cells are white blood cells that have been stimulated with IL-2 in vitro. LAK cells are capable of killing tumor cells both in vitro and in vivo, especially when given along with IL-2. Although this form of treatment has been found to be effective in patients with certain cancers who no longer benefit from standard forms of therapy, the anti-cancer effects of IL-2/LAK cell treatment are limited by the serious, life-threatening side effects of high-dose intravenous administration, and by the high cost. A treatment program with low-dose, intralymphatically-administered LAK/IL-2 in patients with advanced cancer is a promising alternative which circumvents these major problems and concerns, while maintaining high response rates.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Component Transfusion
  • Combined Modality Therapy
  • Humans
  • Immunologic Factors / therapeutic use*
  • Infusions, Intravenous
  • Injections, Intralymphatic
  • Interleukin-2 / administration & dosage*
  • Killer Cells, Lymphokine-Activated / transplantation*
  • Neoplasms / therapy*

Substances

  • Immunologic Factors
  • Interleukin-2